PDF(Pubmed)
Abstract：
UNASSIGNED: Inconsistent results observed in recent phase III trials assessing chimeric antigenic receptor T (CAR-T) cell therapy as a second-line treatment compared to standard of care (SOC) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) prompted a meta-analysis to assess the effectiveness of CAR-T cell therapy in this setting.
UNASSIGNED: Random-effects meta-analysis was conducted to pool effect estimates for comparison between CAR-T cell therapy and SOC. Mixed treatment comparisons were made using a frequentist network meta-analysis approach.
UNASSIGNED: Meta-analysis of three trials with 865 patients showed significant improvement in event-free survival (EFS: HR: 0.51; 95% CI: 0.27-0.97; I2: 92%), progression-free survival (PFS: HR: 0.47; 95% CI: 0.37-0.60; I2: 0%) with CAR-T cell therapy compared to SOC. Although there was a signal of potential overall survival (OS) improvement with CAR-T cell therapy, the difference was not statistically significant between the two groups (HR 0.76; 95% CI: 0.56 to 1.03; I2: 29%). Mixed treatment comparisons showed significant EFS benefit with liso-cel (HR: 0.37; 95% CI: 0.22-0.61) and axi-cel (HR: 0.42; 95% CI: 0.29-0.61) compared to tisa-cel.
UNASSIGNED: CAR-T cell therapy, as a second-line treatment, appears to be effective in achieving higher response rates and delaying the disease progression compared to SOC in R/R DLBCL.
UNASSIGNED: Random-effects meta-analysis was conducted to pool effect estimates for comparison between CAR-T cell therapy and SOC. Mixed treatment comparisons were made using a frequentist network meta-analysis approach.
UNASSIGNED: Meta-analysis of three trials with 865 patients showed significant improvement in event-free survival (EFS: HR: 0.51; 95% CI: 0.27-0.97; I2: 92%), progression-free survival (PFS: HR: 0.47; 95% CI: 0.37-0.60; I2: 0%) with CAR-T cell therapy compared to SOC. Although there was a signal of potential overall survival (OS) improvement with CAR-T cell therapy, the difference was not statistically significant between the two groups (HR 0.76; 95% CI: 0.56 to 1.03; I2: 29%). Mixed treatment comparisons showed significant EFS benefit with liso-cel (HR: 0.37; 95% CI: 0.22-0.61) and axi-cel (HR: 0.42; 95% CI: 0.29-0.61) compared to tisa-cel.
UNASSIGNED: CAR-T cell therapy, as a second-line treatment, appears to be effective in achieving higher response rates and delaying the disease progression compared to SOC in R/R DLBCL.
摘要：
■在最近的III期试验中观察到的结果不一致，该试验评估了嵌合抗原受体T（CAR-T）细胞疗法作为复发性/难治性弥漫性大B患者的二线治疗标准（SOC）细胞淋巴瘤（R/RDLBCL）促使进行荟萃分析以评估CAR-T细胞疗法在这种情况下的有效性。
■进行随机效应荟萃分析以汇集效应估计值，以比较CAR-T细胞疗法和SOC。使用频率网络荟萃分析方法进行混合治疗比较。
■对三个865例患者进行的荟萃分析显示，无事件生存率显着改善（EFS：HR：0.51；95％CI：0.27-0.97；I2：92％），与SOC相比,CAR-T细胞疗法的无进展生存期(PFS:HR:0.47;95%CI:0.37-0.60;I2:0%)。尽管CAR-T细胞疗法有潜在的总生存期（OS）改善的信号，两组之间的差异无统计学意义（HR0.76;95％CI：0.56至1.03;I2：29％）。混合治疗比较显示，与tisa-cel相比，采用Liso-cel（HR：0.37;95％CI：0.22-0.61）和axi-cel（HR：0.42;95％CI：0.29-0.61）的EFS益处显着。
■CAR-T细胞疗法，作为二线治疗，与R/RDLBCL的SOC相比，似乎可有效实现更高的应答率和延迟疾病进展。
■进行随机效应荟萃分析以汇集效应估计值，以比较CAR-T细胞疗法和SOC。使用频率网络荟萃分析方法进行混合治疗比较。
■对三个865例患者进行的荟萃分析显示，无事件生存率显着改善（EFS：HR：0.51；95％CI：0.27-0.97；I2：92％），与SOC相比,CAR-T细胞疗法的无进展生存期(PFS:HR:0.47;95%CI:0.37-0.60;I2:0%)。尽管CAR-T细胞疗法有潜在的总生存期（OS）改善的信号，两组之间的差异无统计学意义（HR0.76;95％CI：0.56至1.03;I2：29％）。混合治疗比较显示，与tisa-cel相比，采用Liso-cel（HR：0.37;95％CI：0.22-0.61）和axi-cel（HR：0.42;95％CI：0.29-0.61）的EFS益处显着。
■CAR-T细胞疗法，作为二线治疗，与R/RDLBCL的SOC相比，似乎可有效实现更高的应答率和延迟疾病进展。
